Evaluation of Flibanserin: Science and Advocacy at the FDA

JAMA. 2015 Sep 1;314(9):869-70. doi: 10.1001/jama.2015.8405.

¹ Division of General Internal Medicine and Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh, Pittsburgh, Pennsylvania2Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania.
² Department of Medicine and Center for Patient Care and Outcomes Research, Medical College of Wisconsin, Milwaukee.
³ Center for Drug Safety and Effectiveness and Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland5Section of General Internal Medicine, Department of Medicine, Johns Hopkins Medicine, Baltimore, Maryland.

No abstract available

Publication types

Advisory Committees
Benzimidazoles / adverse effects
Benzimidazoles / history*
Benzimidazoles / therapeutic use
Consumer Advocacy / history*
Depression / drug therapy
Drug Approval / history*
Drug Approval / methods
Female
History, 21st Century
Humans
Libido / drug effects
National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division
Sexual Dysfunctions, Psychological / drug therapy
Sexual Dysfunctions, Psychological / history*
United States
United States Food and Drug Administration